Today's Breaking News
- Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR
- FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease
- Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX® (daratumumab)
Latest R&D and Business News
- Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for Initiation of a Global Phase 2 Trial for TransCon™ CNP in Children with Achondroplasia
- PMZ-1620, an Endothelin-B Agonist, enters Phase III Trial in Patients with Cerebral Ischemic Stroke
- Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis
- EMA Accepts Samsung Bioepis’ MAA for SB8 Bevacizumab Biosimilar Candidate
- Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
- MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
- Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi Therapeutics For Complement-Mediated Diseases
- Inflection Biosciences and AUM Biosciences Announce Global License Agreement for PIM/PI3K/mTOR Inhibitors
- Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
- MacroGenics Provides Update on Flotetuzumab Program in Acute Myeloid Leukemia
- Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
- Bayer, Bristol-Myers Squibb and Ono Pharmaceutical Enter Into a Clinical Collaboration Agreement to Investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as Combination Therapy in Patients With Metastatic Colorectal Cancer